Erytech Pharma ()

Founded in Lyon (France) in 2004, Erytech Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, Erytech has developed a pipeline of product candidates targeting markets with high unmet medical needs. Erytech’s initial focus is on the treatment of cancers, by depriving tumors of nutrients necessary for their survival.

Role and Commitment of key persons (including supervisors)

Dr. Alexander Scheer, CSO, overall supervision (20%) Dr. Agnès Cibiel, Project Manager, supervision (80%)

Key Research Facilities, Infrastructure and Equipment

Erytech Pharma has state-of-the-art equipments essential for developing novel RBC based therapeutic products. Infrastructures include fully equipped cell culture and molecular biology labs with automated hematology analyzers, flow cytometer, incucyte, and access to LORRCA system necessary to characterize engineered RBC properties. In addition, a team of 35 highly qualified research technicians, engineers and scientists will be involved in the research supervision and training of the recruited Early-Stage Researchers.

Status of Research Premises

Erytech Pharma is renting its own independent space in Bioparc Lyon. Erytech possesses its ERYCAPS platform to encapsulate therapeutic molecules into RBC. Erytech possesses also its own equipment to characterize RBC before and after encapsulation process.

Previous Involvement in Research and Training Programmes

Current Involvement in Research and Training Programmes

Relevant Publications and/ or Research/ Innovation Product